PBYI Stock Forecast: Puma Biotechnology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Puma Biotechnology, Inc. is $8.25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 98 of 100 as at 21 Nov 2026 — among the strongest tenth.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Puma Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (41): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PBYI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PBYI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | TD Cowen | Maintains | Hold | $5.00 → $6.00 |
| 28 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 23 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Aug 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Aug 2022 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PBYI.
This page is one stock. Monday covers all of them.
PBYI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PBYI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Puma Biotechnology, Inc. returned +45.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PBYI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 15.6×
- Price / sales
- 1.6×
- Price / book
- 2.5×
- EV / EBITDA
- 7.4×
Cheaper than 55% of US stocks
Cheaper than 54% of US stocks
Cheaper than 36% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −32.7%
- Gross margin
- 77.9%
- Operating margin
- 11.3%
- Net margin
- 10.3%
Higher than 15% of US stocks
Higher than 89% of US stocks
Higher than 66% of US stocks
Higher than 68% of US stocks
- Return on equity
- 18.2%
- Return on assets
- 8.1%
- Dividend yield
- —
Higher than 79% of US stocks
Higher than 88% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Puma Biotechnology, Inc. has a market value of $368.1M and an enterprise value of $264.4M.
Revenue in the twelve months to 30 June 2026: $231.2M. The latest quarter grew 7.8% year on year.
Net income over the same four quarters: $26.7M, a 11.6% net margin.
Diluted earnings per share, trailing twelve months: $0.52.
Free cash flow in the twelve months to 30 June 2026: $41.2M.
Trailing P/E: 15.6×; forward P/E: 20.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Puma Biotechnology, Inc. employs 179 people — $1.3M of revenue per employee.
Data provided by Twelve Data
PBYI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PBYI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Puma Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PBYI
What is the PBYI stock price forecast for 2026-2027?
The median 12-month analyst price target for Puma Biotechnology, Inc. is $8.25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PBYI stock a buy right now?
Of the 1 analyst covering Puma Biotechnology, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Puma Biotechnology, Inc. 98 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PBYI?
As at 21 Nov 2026, Puma Biotechnology, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
Will PBYI stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $8.25, and Ticker Nerd's factor model ranks Puma Biotechnology, Inc. 98 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PBYI stock forecast for 2030?
No analyst covering Puma Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBYI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.25 to $8.25 over the next 12 months.
How has PBYI stock performed over the past year?
Puma Biotechnology, Inc. returned +45.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Puma Biotechnology, Inc. do?
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types.
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing therapies that support cancer care. Its current portfolio centers on NERLYNX, an oral treatment based on neratinib used in specific HER2-positive breast cancer settings, along with alisertib, an investigational oncology candidate being studied across several tumor types. The company works through specialty pharmacy and distributor networks and maintains licensing and collaboration agreements that support the development, manufacture, and commercialization of its cancer-focused products. Puma Biotechnology serves patients and healthcare providers in the United States and select international markets, with an emphasis on targeted therapies for oncology. Based in Los Angeles, California, Puma Biotechnology plays a specialized role in the biotechnology market by concentrating on molecularly targeted cancer treatments and late-stage product commercialization.
CEO Mr. Alan H. Auerbach · 179 employees · United States · https://www.pumabiotechnology.com